Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)

  • Technology appraisal
  • TA933
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence